132 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Clinical Pharmacology Audio PeerVoice

    • Science
    • 2.0 • 1 Rating

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    Evaluating the Evidence for SGLT2 Inhibition in CKD

    Evaluating the Evidence for SGLT2 Inhibition in CKD

    Go online to peervoice.com/QSX860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

    • 19 min
    Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?

    Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?

    Go online to peervoice.com/YZK860 to view the entire programme with slides. After completing “Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

    • 36 min
    A Look at Emerging SMA Outcomes: Highlights of CureSMA 2020

    A Look at Emerging SMA Outcomes: Highlights of CureSMA 2020

    Go online to peervoice.com/GWW860 to view the entire programme with slides. After completing “A Look at Emerging SMA Outcomes: Highlights of CureSMA 2020”, participants will be able to: Describe the pathogenesis of SMA in terms of potential therapeutic targets; Review current progress in terms of diagnosis and management; and Analyse clinical evidence for novel therapeutic targets in terms of outcomes and safety.

    • 9 min
    A Look at Emerging SMA Outcomes: Highlights of EAN 2020

    A Look at Emerging SMA Outcomes: Highlights of EAN 2020

    Go online to peervoice.com/XBY860 to view the entire programme with slides. After completing “A Look at Emerging SMA Outcomes: Highlights of EAN 2020”, participants will be able to: Describe the pathogenesis of SMA in terms of potential therapeutic targets; Review current progress in terms of diagnosis and management; and Analyse clinical evidence for novel therapeutic targets in terms of outcomes and safety.

    • 9 min
    Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs

    Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs

    Go online to peervoice.com/PSA860 to view the entire programme with slides. After completing “Deciphering the Role of MET Alterations in Advanced NSCLC: Unmet Needs”, participants will be able to: Describe the unmet treatment needs in patients with advanced non–small-cell lung cancer (NSCLC), and in particular MET exon 14 (METex14) skipping mutations; Summarise the impact of METex14 mutation on patient outcomes; and Discuss current and emerging treatment options for patients with METex14 mutations.

    • 15 min
    New Targets in IBD: Focus on IL-23

    New Targets in IBD: Focus on IL-23

    Go online to peervoice.com/HHK860 to view the entire programme with slides. After completing “New Targets in IBD: Focus on IL-23”, participants will be able to: Explain the rationale for targeting IL-23 in inflammatory bowel disease (IBD); Evaluate the relative efficacy and safety of IL-23 inhibitors to date for patients with IBD; and Describe how these agents may fit into future treatment algorithms for IBD.

    • 18 min

Customer Reviews

2.0 out of 5
1 Rating

1 Rating

Top Podcasts In Science

Listeners Also Subscribed To